WO1996024612A1 - Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO1996024612A1 WO1996024612A1 PCT/FR1996/000199 FR9600199W WO9624612A1 WO 1996024612 A1 WO1996024612 A1 WO 1996024612A1 FR 9600199 W FR9600199 W FR 9600199W WO 9624612 A1 WO9624612 A1 WO 9624612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- hydrogen atom
- carbon atoms
- atom
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to new famesy] transferase inhibitors of general formula:
- the inhibition of fainesyl transferase and, therefore, of famesylation of the ras protein blocks the ability of the mutated ras protein to transform normal cells into cancer cells.
- the C-terminal sequence of the ras gene contains the motif "CAAX” or "Cys-Aaa ⁇ -Aaa2-Xaa” in which Aaa represents an aliphatic amino acid and Xaa represents any amino acid.
- tetrapeptides with a CAAX sequence can inhibit famesylation of the ras protein.
- peptides inhibitors of the famesyl transferase Cys-Aaa ⁇ -Aaa2-Xaa which are more particularly represented by the peptides Cys-Val-Leu- Ser, Cys-Val-Ile-Met and Cys-Val-Val-Met which show their inhibitory activity at concentrations close to 10 "" M or 0 10-7M.
- Rj represents a radical of general formula YS-Aj- in which Y represents a hydrogen atom, or an amino acid residue or a fatty acid residue or an alkyl or alkoxycarbonyl radical, or a radical R4-S- in which R4 represents a radical alkyl containing 1 to 6 carbon atoms optionally substituted by a phenyl radical or a radical of general formula:
- R2 represents a straight or branched alkyl radical containing 1 to 4 carbon atoms optionally substituted by a cyclohexyl radical
- R'2 represents a hydrogen atom or a straight or branched alkyl radical containing 1 to 6 carbon atoms
- R3 represents an alkyl radical containing straight or branched containing 1 to 4 carbon atoms optionally substituted by a hydroxy radical, alkoxy containing 1 to 4 carbon atoms, mercapto, alkylthio containing 1 to 4 carbon atoms, alkylsulfinyl containing 1 to 4 carbon atoms or alkylsulfonyl containing 1 to 4 carbon atoms, it being understood that, when R3 represents an alkyl radical substituted by a hydroxy radical, R3 can form with the carboxy radical in ⁇ a lactone, R'3 represents a hydrogen atom or a straight or branched alkyl radical containing 1 to 6 carbon atoms,
- X represents an oxygen or sulfur atom
- R represents a hydrogen atom or an alkyl radical optionally substituted by an alkoxy radical containing 1 to 4 carbon atoms, alkylthio containing 1 to 4 carbon atoms, alkylsulfinyl containing 1 to 4 carbon atoms, alkylsulfonyl containing 1 to 4 carbon atoms, phenyl, phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl, alkylamino containing 1 to 4 carbon atoms or dialkylamino each alkyl part of which contains 1 to 4 carbon atoms, or a phenyl radical optionally substituted by one or more identical or different atoms or radicals chosen from halogen atoms and alkyl, alkoxy, alkylthio or alkanoyl radicals containing 1 to 4 carbon atoms. More specifically,
- R j represents a radical of formula YS-Aj- in which Y represents a hydrogen atom or a lysine residue or a fatty acid residue containing up to 20 carbon atoms and A] represents an optionally substituted ethylene or propylene radical by an amino radical,
- R2 represents an isopropyl, 1-methylpropyl, tert-butyl or cyclohexylmethyl radical
- R'2 represents a hydrogen atom or a methyl radical
- R3 represents a methyl or ethyl radical substituted by a hydroxy, methoxy, mercapto, methylthio, methylsulfinyl or methylsulfonyl radical,
- R'3 represents a hydrogen atom or a methyl radical
- X represents an oxygen atom
- R represents a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms optionally substituted by an alkoxy radical, or a phenyl radical. More particularly still,
- Ri represents a radical of formula Y-S-Aj- in which Y represents a hydrogen atom and Aj represents an ethylene or propylene radical optionally substituted by an amino radical,
- Xj and Yi each represent a hydrogen atom or together form with the carbon atom to which they are linked a group> CO,
- R2 represents an isopropyl, 1-methyl propyl, tert-butyl or cyclohexyl methyl radical
- R'2 represents a hydrogen atom
- R represents a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms.
- R 1 represents a 2-mercapto-ethyl or 2-amino-2-mercapto-ethyl radical
- Xj and Y each represent a hydrogen atom or form together with the atom of carbon to which they are linked a group> CO
- R2 represents an isopropyl radical
- R'2 represents a hydrogen atom
- R3 represents a 2-methylthioethyl or 2-methylsulfinylethyl radical
- R'3 represents a hydrogen atom
- R represents a hydrogen atom.
- the present invention also relates to the stereoisomeric forms of the products of general formula (I).
- the amino acid residues represented by R] C (X ⁇ ) (Y ⁇ ), R2CH (NR ' 2 ) [C (X2) (Y2)] and R 3 CH (NR' 3 ) CO-OH preferably have the amino acid configuration natural.
- the present invention also relates to the mineral or organic salts as well as the esters of the products of general formula (I).
- the new products of general formula (I) can be obtained by solid phase synthesis using a synthesis strategy "9-fluorenylmethoxycarbonyl (FMOC)".
- FMOC 9-fluorenylmethoxycarbonyl
- the thiol groups are protected by trityl or acetamidomethyl groups
- the amino functions by Boc groups (t.butoxycarbonyl) and the acid functions in the form of t.butyl ester
- the amide and imidazole functions by trityl groups can be carried out on a resin confined in syringes of solid phase extraction of 3 cm3 in high density polyethylene provided with teflon filters.
- the syringes are mounted on a two-way teflon valve and closed by a disposable wing plug made of high density polyethylene.
- the syringes are shaken on a rotary device for hemolysis tubes.
- the washing and filtration operations are carried out on a solid phase extraction workstation.
- the syntheses can be carried out on 50 ⁇ moles of resin.
- Amino acid couplings are carried out by treating the resin for 1 hour with 250 ⁇ moles amino acid suitably protected in the presence of 250 ⁇ moles of 2- (1H- benzotriazole-1-yl) -l, l, 3,3-tetramethyluronium, hexafluorophosphate (HBTU), 250 ⁇ moles of N-hydoxybenzotriazole and 750 ⁇ moles of diisopropylethylamine in 1.2 cm3 of an N-methylpyrrolidone-2 (NMP) / dimethylformamide mixture (1/1 by volume).
- NMP N-methylpyrrolidone-2
- Deprotection of the FMOC group is carried out by 3 successive treatments of the resin for 2 times 1 minute then 20 minutes with 2 cm 3 of piperidine in 2% solution (v / v) in NMP.
- Cys- (NMe) Val - [(R, S) -tetrahydro-1,2,3,4-isoquinoline-1-carbonyl] -Met can be prepared as follows: 50 ⁇ moles of Fmoc-Met resin [Wang resin;
- the products are separated by treating the resin with 10 cm 3 of a trifluoroacetic acid-phenol-ethanedithiol-thioanisole-water mixture (40-3-1-2-2 by volume) for 1 hour 30 minutes.
- the resin is then removed by filtration.
- the filtrate is concentrated under reduced pressure by means of a centrifugal evaporator (RC10-10 Jouan) equipped with a vane pump and a trap at -90 ° C for 1.5 hours, the temperature of the evaporation being maintained at 50 ° C.
- the final volume of the concentrate is approximately 1 cm3.
- the product is then precipitated by adding 15 cm3 of a mixture of methyl-tert-butyl ether and petroleum ether (2-1 by volume), then it is collected by centrifugation.
- the pellet is then dissolved in 1 cm3 of trifluoroacetic acid, precipitated by addition of 15 cm3 of methyl-tert-butyl ether and then washed with 15 cm3 of methyl-tert-butyl ether.
- the product is then dried under reduced pressure (3.5 kPa).
- the product is finally purified by high performance liquid chromatography (HPLC) on a Cl 8,100 A column (250 x 10 mm, BioRad) eluted with an acetonitrile gradient containing 0.07% trifluoroacetic acid (by volume) in water containing 0.07% trifluoroacetic acid (by volume) at a flow rate of 6 cm3 / min and then lyophilized.
- HPLC high performance liquid chromatography
- Tetrahydro-1,2,3,4-isoquinoline-1-carboxylic acid in racemic form can be prepared by hydrogenation of isoquinoline-1-carboxylic acid under the conditions described by RT Shuman et al., J. Med . Chem., __, 314 (1993).
- the FMOC protective group is introduced onto an amino acid by the action of the amino acid on 9-fluorenylmethyl chloroformate (FMOC-chloride) in the presence of a base.
- the farnesyltransferase and famesylation inhibitory activity of the Ras protein can be demonstrated in the following test:
- the farnesyltransferase activity is determined by the amount of ( ⁇ H) famesyl transferred from H) famesylpyrophosphate [H) FPP) to the p21 H-ras protein.
- the standard reaction mixture is composed, for a final volume of 60 ⁇ l, of 50 mM Tris-HCl, 5 mM MgCl2, 5 mM dithiotreitol, octyl- ⁇ -D-glucopyranoside 0.2%, p21 H-ras 200 picomoles, ( ⁇ H ) FPP (at 61,000 dpm / picomole) 4.5 picomoles.
- the reaction is initiated by the addition of approximately 5 ng of human farnesyltransferase purified from cultures of THP1 cells. After incubation for 20 minutes at 37 ° C. in a microtiter plate containing 96 holes of 1 cm 3 per plate (Titer Plate®, Beckman), the reaction is stopped by adding 0.4 cm 3 of 0.1% SDS in methanol. at 0 ° C. 0.4 cm 3 of trichloroacetic acid (TCA) 30% in methanol is then added to the mixture. The plates are left for 1 hour in ice.
- TCA trichloroacetic acid
- the precipitated content is then retained on a fiberglass® filtermat® membrane, Pharmacia) with the filtration unit (Combi Cell Harvester®, Skatron) and rinsed with 6% trichloroacetic acid in distilled water.
- the membranes are dried in the microwave oven then impregnated with scintillant by melting under hot air with Meltilex® (Pharmacia) and finally counted in cpm in a ⁇ -Plate® counter (LKB). Each test is repeated 3 times.
- the activity unit is defined by 1 picomole of H) FPP transferred to p21 H-ras in 20 minutes.
- the inhibition percentages are obtained by comparison of the tests with and without inhibitor after deduction of the blanks, the IC50 being measured from the inhibitions obtained with 9 different concentrations using the Enzfitter® or Graf it® software.
- the new peptides of general formula (I) can be in the form of non-toxic and pharmaceutically acceptable salts.
- These non-toxic salts include the salts with mineral acids (hydrochloric, sulfuric, hydrobromic, phosphoric, nitric) or with organic acids (acetic, propionic, succinic, maleic, hydroxymaleic, benzoic, fumaric, methanesulfonic, trifluoroacetic or oxalic acids) or with mineral bases (soda, potash, lithine, lime) or organic bases (tertiary amines such as triethylamine, piperidine, benzylamine) depending on the nature of the amino acids which constitute the peptide of general formula (I).
- the new peptides according to the invention which inhibit farnesyltransferase and famesylation of the Ras protein, are remarkable anticancer agents which act both in solid and liquid tumors.
- the present invention also relates to pharmaceutical compositions which contain at least one peptide of general formula (I) in combination with one or more diluents or pharmaceutically acceptable adjuvants whether inert or physiologically active.
- compositions can be administered orally, parenterally or rectally.
- compositions for oral administration include tablets, pills, powders or granules.
- the active product according to the invention is mixed with one or more inert diluents such as sucrose, lactose or starch.
- these compositions can include substances other than diluents, for example a lubricant such as magnesium stearate.
- compositions for oral administration can be used pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs containing inert diluents such as water or paraffin oil.
- diluents such as water or paraffin oil.
- These compositions can also include substances other than diluents, for example wetting, sweetening or flavoring products.
- compositions according to the invention for parenteral administration can be sterile aqueous or non-aqueous solutions, suspensions or emulsions.
- solvent or vehicle propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil or injectable organic esters, for example ethyl oleate.
- These compositions can also contain adjuvants, in particular wetting agents, emulsifiers and dispersants. Sterilization can be done in several ways, for example using a bacteriological filter, incorporating sterilizing agents into the composition or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- the compositions for rectal administration are suppositories which may contain, in addition to the active product, excipients such as cocoa butter.
- compositions according to the invention are particularly useful in human therapy in the treatment of cancers of various origins.
- the doses depend on the desired effect, on the duration of the treatment and on the factors specific to the subject to be treated.
- the doses are, in humans, between 0.1 and 20 mg / kg per day intraperitoneally.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8524038A JPH10513468A (ja) | 1995-02-09 | 1996-02-07 | ファルネシル転移酵素阻害剤、これらの調製、及びこれらを含む製薬学的組成 |
EP96903062A EP0808329A1 (fr) | 1995-02-09 | 1996-02-07 | Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
SK1088-97A SK108897A3 (en) | 1995-02-09 | 1996-02-07 | Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same |
PL96321710A PL321710A1 (en) | 1995-02-09 | 1996-02-07 | Novel inhibitors of farnseferase, their production and pharmaceutic compositions containing them |
BR9607318A BR9607318A (pt) | 1995-02-09 | 1996-02-07 | Peptidos e composição farmacêutica |
AU47228/96A AU4722896A (en) | 1995-02-09 | 1996-02-07 | Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same |
CZ972499A CZ249997A3 (en) | 1995-02-09 | 1996-02-07 | Novel inhibitors of farnesyl transferase, process of their preparation and pharmaceutical compositions containing such inhibitors |
NO973607A NO973607D0 (no) | 1995-02-09 | 1997-08-05 | Nye farnesyltransferaseinhibitorer, deres fremstilling og preparater inneholdende inhibitorene |
MXPA/A/1997/005969A MXPA97005969A (en) | 1995-02-09 | 1997-08-05 | New farnesil inhibitors transfer your preparation and the pharmaceutical compositions that contain them |
FI973279A FI973279A0 (fi) | 1995-02-09 | 1997-08-08 | Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9501490A FR2730492B1 (fr) | 1995-02-09 | 1995-02-09 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR95/01490 | 1995-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996024612A1 true WO1996024612A1 (fr) | 1996-08-15 |
Family
ID=9475981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/000199 WO1996024612A1 (fr) | 1995-02-09 | 1996-02-07 | Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0808329A1 (fr) |
JP (1) | JPH10513468A (fr) |
KR (1) | KR19980702049A (fr) |
CN (1) | CN1173873A (fr) |
AU (1) | AU4722896A (fr) |
BR (1) | BR9607318A (fr) |
CA (1) | CA2210953A1 (fr) |
CZ (1) | CZ249997A3 (fr) |
FI (1) | FI973279A0 (fr) |
FR (1) | FR2730492B1 (fr) |
NO (1) | NO973607D0 (fr) |
PL (1) | PL321710A1 (fr) |
SK (1) | SK108897A3 (fr) |
TR (1) | TR199700726T1 (fr) |
WO (1) | WO1996024612A1 (fr) |
ZA (1) | ZA961073B (fr) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856439A (en) * | 1995-02-09 | 1999-01-05 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same |
US5932590A (en) * | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5972966A (en) * | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6015817A (en) * | 1996-12-05 | 2000-01-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
FR2796943A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique |
FR2796946A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique |
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
WO2007093827A1 (fr) | 2006-02-15 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac) |
WO2008106692A1 (fr) | 2007-03-01 | 2008-09-04 | Novartis Vaccines And Diagnostics, Inc. | Inhibiteurs de pim kinase et procédés de leur utilisation |
WO2008144062A1 (fr) | 2007-05-21 | 2008-11-27 | Novartis Ag | Inhibiteurs du csf-1r, compositions et procédés d'utilisation |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
EP2336120A1 (fr) | 2007-01-10 | 2011-06-22 | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. | Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP) |
WO2011115725A2 (fr) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Composés d'indazole et leurs utilisations |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
WO2012024170A2 (fr) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
WO2012058210A1 (fr) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA) |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
WO2014085216A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions et procédés pour traiter le cancer |
WO2014100065A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituées en tant qu'inhibiteurs de hdm2 |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
WO2016020864A1 (fr) | 2014-08-06 | 2016-02-11 | Novartis Ag | Inhibiteurs de protéine kinase c et leurs procédés d'utilisation |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2018058022A1 (fr) | 2016-09-26 | 2018-03-29 | Merck Sharp & Dohme Corp. | Anticorps anti-cd27 |
WO2018071283A1 (fr) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Inhibiteurs de kdm5 |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2018190719A2 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10144730B2 (en) | 2011-11-17 | 2018-12-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2019152642A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10906889B2 (en) | 2013-10-18 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
US11040957B2 (en) | 2013-10-18 | 2021-06-22 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
US11096950B2 (en) | 2006-11-01 | 2021-08-24 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016340A1 (fr) * | 1990-04-18 | 1991-10-31 | Board Of Regents, The University Of Texas System | Procedes et compositions servant a l'identification, a la caracterisation et a l'inhibition de la transferase de proteine farnesyle |
EP0523873A1 (fr) * | 1991-06-28 | 1993-01-20 | Merck & Co. Inc. | Inhibiteurs non-substrat peptidiques de la farnesyl-protéine-transferase |
EP0618221A2 (fr) * | 1993-04-02 | 1994-10-05 | Bristol-Myers Squibb Company | Inhibiteurs hétérocycliques de la farnesyl-protein-transferase |
WO1994026723A2 (fr) * | 1993-05-14 | 1994-11-24 | Genentech, Inc. | INHIBITEURS DE LA ras FARNESYL-TRANSFERASE |
WO1995025092A1 (fr) * | 1994-03-14 | 1995-09-21 | Merck & Co., Inc. | Inhibiteurs de la proteine farnesyl-transferase |
-
1995
- 1995-02-09 FR FR9501490A patent/FR2730492B1/fr not_active Expired - Fee Related
-
1996
- 1996-02-07 BR BR9607318A patent/BR9607318A/pt not_active Application Discontinuation
- 1996-02-07 JP JP8524038A patent/JPH10513468A/ja active Pending
- 1996-02-07 WO PCT/FR1996/000199 patent/WO1996024612A1/fr not_active Application Discontinuation
- 1996-02-07 CN CN96191866A patent/CN1173873A/zh active Pending
- 1996-02-07 PL PL96321710A patent/PL321710A1/xx unknown
- 1996-02-07 SK SK1088-97A patent/SK108897A3/sk unknown
- 1996-02-07 EP EP96903062A patent/EP0808329A1/fr not_active Withdrawn
- 1996-02-07 CZ CZ972499A patent/CZ249997A3/cs unknown
- 1996-02-07 AU AU47228/96A patent/AU4722896A/en not_active Abandoned
- 1996-02-07 CA CA002210953A patent/CA2210953A1/fr not_active Abandoned
- 1996-02-07 TR TR97/00726T patent/TR199700726T1/xx unknown
- 1996-02-07 KR KR1019970705444A patent/KR19980702049A/ko not_active Application Discontinuation
- 1996-02-09 ZA ZA961073A patent/ZA961073B/xx unknown
-
1997
- 1997-08-05 NO NO973607A patent/NO973607D0/no unknown
- 1997-08-08 FI FI973279A patent/FI973279A0/fi not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016340A1 (fr) * | 1990-04-18 | 1991-10-31 | Board Of Regents, The University Of Texas System | Procedes et compositions servant a l'identification, a la caracterisation et a l'inhibition de la transferase de proteine farnesyle |
EP0523873A1 (fr) * | 1991-06-28 | 1993-01-20 | Merck & Co. Inc. | Inhibiteurs non-substrat peptidiques de la farnesyl-protéine-transferase |
EP0618221A2 (fr) * | 1993-04-02 | 1994-10-05 | Bristol-Myers Squibb Company | Inhibiteurs hétérocycliques de la farnesyl-protein-transferase |
WO1994026723A2 (fr) * | 1993-05-14 | 1994-11-24 | Genentech, Inc. | INHIBITEURS DE LA ras FARNESYL-TRANSFERASE |
WO1995025092A1 (fr) * | 1994-03-14 | 1995-09-21 | Merck & Co., Inc. | Inhibiteurs de la proteine farnesyl-transferase |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856439A (en) * | 1995-02-09 | 1999-01-05 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same |
US5932590A (en) * | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5972966A (en) * | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6015817A (en) * | 1996-12-05 | 2000-01-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
FR2796946A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique |
WO2001009127A1 (fr) * | 1999-07-30 | 2001-02-08 | Aventis Pharma S.A. | Derives de benzoxazines, leur procede de preparation et leur utilisation en therapeutique |
WO2001009124A1 (fr) * | 1999-07-30 | 2001-02-08 | Aventis Pharma S.A. | Derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapique |
FR2796943A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique |
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
WO2007093827A1 (fr) | 2006-02-15 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac) |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
EP2946778A1 (fr) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras |
US11096950B2 (en) | 2006-11-01 | 2021-08-24 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2336120A1 (fr) | 2007-01-10 | 2011-06-22 | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. | Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP) |
EP2805945A1 (fr) | 2007-01-10 | 2014-11-26 | MSD Italia S.r.l. | Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase |
WO2008106692A1 (fr) | 2007-03-01 | 2008-09-04 | Novartis Vaccines And Diagnostics, Inc. | Inhibiteurs de pim kinase et procédés de leur utilisation |
WO2008144062A1 (fr) | 2007-05-21 | 2008-11-27 | Novartis Ag | Inhibiteurs du csf-1r, compositions et procédés d'utilisation |
EP3103791A1 (fr) | 2007-06-27 | 2016-12-14 | Merck Sharp & Dohme Corp. | Dérivés de4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
US9505784B2 (en) | 2009-06-12 | 2016-11-29 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
WO2011115725A2 (fr) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Composés d'indazole et leurs utilisations |
US8987275B2 (en) | 2010-03-16 | 2015-03-24 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
EP3330377A1 (fr) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
WO2012024170A2 (fr) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
EP4079856A1 (fr) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
WO2012058210A1 (fr) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA) |
EP3327125A1 (fr) | 2010-10-29 | 2018-05-30 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
US10981903B2 (en) | 2011-11-17 | 2021-04-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US10144730B2 (en) | 2011-11-17 | 2018-12-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
EP3919620A1 (fr) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
US10787436B2 (en) | 2012-10-18 | 2020-09-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014085216A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions et procédés pour traiter le cancer |
WO2014100065A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituées en tant qu'inhibiteurs de hdm2 |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
US11040957B2 (en) | 2013-10-18 | 2021-06-22 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
US10906889B2 (en) | 2013-10-18 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
EP3514151A1 (fr) | 2014-08-06 | 2019-07-24 | Novartis AG | Inhibiteurs de protéine kinase c et leurs procédés d'utilisation |
WO2016020864A1 (fr) | 2014-08-06 | 2016-02-11 | Novartis Ag | Inhibiteurs de protéine kinase c et leurs procédés d'utilisation |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US11325910B2 (en) | 2015-03-27 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2018058022A1 (fr) | 2016-09-26 | 2018-03-29 | Merck Sharp & Dohme Corp. | Anticorps anti-cd27 |
WO2018071283A1 (fr) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Inhibiteurs de kdm5 |
WO2018190719A2 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2019152642A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JPH10513468A (ja) | 1998-12-22 |
BR9607318A (pt) | 1997-12-30 |
KR19980702049A (ko) | 1998-07-15 |
FR2730492A1 (fr) | 1996-08-14 |
FI973279A (fi) | 1997-08-08 |
CA2210953A1 (fr) | 1996-08-15 |
FR2730492B1 (fr) | 1997-03-14 |
AU4722896A (en) | 1996-08-27 |
PL321710A1 (en) | 1997-12-22 |
EP0808329A1 (fr) | 1997-11-26 |
NO973607L (no) | 1997-08-05 |
NO973607D0 (no) | 1997-08-05 |
FI973279A0 (fi) | 1997-08-08 |
ZA961073B (en) | 1996-08-20 |
CZ249997A3 (en) | 1997-11-12 |
MX9705969A (es) | 1997-11-29 |
CN1173873A (zh) | 1998-02-18 |
SK108897A3 (en) | 1997-12-10 |
TR199700726T1 (xx) | 1998-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996024612A1 (fr) | Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1996024611A1 (fr) | Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0764149B1 (fr) | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1997003047A1 (fr) | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1996022278A1 (fr) | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent | |
AU714147B2 (en) | Inhibitors of farnesyl protein transferase | |
US5801274A (en) | N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives | |
LU82316A1 (fr) | Mercaptoacyldipeptides a action anti-hypertensive | |
FR2496654A1 (fr) | Nouveaux tri-, tetra- et pentapeptides, leur preparation et les medicaments qui les contiennent | |
FR2721021A1 (fr) | Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent. | |
EP0188947B1 (fr) | Peptides réduits, inhibiteurs de la sécrétion gastrique, procédé d'obtention et compositions pharmaceutiques les contenant | |
CH647789A5 (fr) | Tripeptides, leur preparation et les medicaments qui les contiennent. | |
FR2468589A1 (fr) | Derives aminoacyles de mercaptoacyl amino-acides, a action antihypertensive | |
FR2491922A1 (fr) | Nouveaux hexapeptides, procede pour leur preparation et application comme medicaments | |
JPH024748A (ja) | 薬理作用を有するペプチド類 | |
CH644858A5 (fr) | Derives du (pyridyl-2)-2 tetrahydrothiophene, leur preparation et les medicaments qui les contiennent. | |
FR2634763A1 (fr) | Amino-acides et peptides presentant un residu tyrosine modifiee, leur preparation et leur application comme medicaments | |
FR2725717A1 (fr) | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent | |
MXPA97006015A (en) | Novedous inhibitors of farnesil transferase, supreparation and pharmaceutical compositions chelos contie | |
MXPA97005969A (en) | New farnesil inhibitors transfer your preparation and the pharmaceutical compositions that contain them | |
BE844377R (fr) | Peptides | |
FR2469395A1 (fr) | Nouveau cyclopeptide, sa preparation et les medicaments qui le contiennent | |
FR2665703A1 (fr) | Nouvelles microproteines, procede de preparation et application a titre de medicaments de ces nouvelles microproteines. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96191866.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IS JP KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AZ BY KG KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996903062 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2210953 Country of ref document: CA Ref document number: 2210953 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 97/00726 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 1997 875750 Country of ref document: US Date of ref document: 19970801 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1996 524038 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 301735 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/005969 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-2499 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 108897 Country of ref document: SK Ref document number: 1019970705444 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 973279 Country of ref document: FI Ref document number: 97-01503 Country of ref document: RO |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-2499 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996903062 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705444 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996903062 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-2499 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970705444 Country of ref document: KR |